Stress disorders like PTSD and adjustment disorder were linked to adverse cardiovascular outcomes in a recent BMJ study, Reuters reports, with the greatest CV risk posed in the months directly after a patient is diagnosed with such a condition.

Catheter-directed therapy (CDT) is being used to treat pulmonary embolism (PE) more and more by healthcare providers, according to new research published in the Journal of Vascular and Interventional Radiology.

MicroRNAs could be key to treating heart failure, according to a study out of Boston Children’s Hospital and Zhejiang University School of Medicine in China.

Prior authorization practices are a significant problem that cause delays in patient care, according to a new survey of more than 650 practicing radiation oncologists.

A national effort to recall carcinogen-tainted batches of the popular blood pressure drug losartan has once again expanded, growing to include one lot of the medication distributed by Legacy Pharmaceutical Packaging, LLC.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.